Product Description: Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Weiss SA, et al. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. Clin Cancer Res. 2021 Sep 1;27(17):4757-4767. /[2]Peyraud F, et al. CSF-1R Inhibitor Development: Current Clinical Status. Curr Oncol Rep. 2017 Sep 5;19(11):70.
CAS Number: 1613144-80-1
Molecular Weight: N/A
Compound Purity: 99.59
Research Area: Cancer; Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: c-Fms
English
Deutsch
